#USA #Boston #Morphic Medical #RESET #Dr. Terri Cooper

Morphic Medical Expands Leadership for Future Growth

On August 6, 2026, Morphic Medical, a pioneer in developing the first medical device targeting the root causes of Type 2 diabetes, made significant strides in corporate governance by appointing Dr. Terri Cooper as Chair of the Board and Craig Richardson as a new board member. This move comes at a pivotal time as the company looks to enhance its presence in international markets following the successful certification of its flagship product, RESET.

Dr. Cooper, with her extensive background in healthcare entrepreneurship, will work closely with company executives and fellow board members to drive strategic growth and ensure company governance aligns with the organization's long-term vision. “Morphic Medical has developed an exciting and unique technology that has the potential to revolutionize treatment pathways for obesity and metabolic diseases,” Cooper remarked. Her leadership is anticipated to steer the company through a critical growth period, especially after achieving important clinical, regulatory, and marketing milestones in Europe.

Craig Richardson brings a wealth of expertise in health economics and market access to his role. He is set to play a key role in articulating the clinical and economic benefits of RESET as Morphic Medical engages with payers, providers, and policymakers to broaden patient access. “As the burden of healthcare systems caused by obesity and Type 2 diabetes grows globally, it remains essential for innovative therapies to demonstrate both compelling clinical outcomes and economic value,” Richardson stated. His insights are expected to be invaluable as the company continues to advocate compelling health economic evidence across key markets.

Morphic Medical board chair Mike Gutteridge expressed gratitude towards former board chair Mark Lerdal for his leadership during his tenure. “We are thrilled to welcome Terri and Craig to our board as we progress. Their strategic leadership capabilities and deep experience in building successful healthcare organizations position them perfectly to guide Morphic Medical through its next phase of growth,” said Gutteridge. Cooper and Richardson's combined expertise is seen as a significant asset as Morphic Medical focuses on improving the quality of life for patients suffering from obesity and Type 2 diabetes.

Morphic Medical’s announcement of these appointments reflects its commitment to building a premier board equipped with the necessary expertise to support the company's business strategy, international expansion, and long-term mission—to enhance treatment outcomes for patients with obesity and Type 2 diabetes.

About Morphic Medical

Founded in 2003 and headquartered in Boston, Massachusetts, Morphic Medical is dedicated to developing RESET, an endoscopically delivered therapy offering a non-surgical alternative for treating severe obesity and/or obesity linked to cardiometabolic risk factors like Type 2 diabetes and dyslipidemia. Currently, RESET is approved for sale in the EU and the UK and is restricted to research use in the US. To learn more, visit morphicmedical.com or follow on Twitter and LinkedIn.